The University of Virginia paricipated in a national study, funded through the National Institutes of Health (NIH), assessing infection, viral shedding, and transmission risks among college students who received the Moderna COVID-19 vaccine two-dose series. The study (COVPN 3006) was conducted to determine the Moderna vaccine’s effectiveness in preventing infection among college students, and to better understand if the vaccine prevents asymptomatic infection and how it reduces the risk of transmission to others.
- All media inquires related to this study, please contact Brian Coy.
- Read the UVAToday story about this vaccination study.
NOTE: University and UVA Health leaders stress that UVA’s participation in the vaccine study in no way affected the availability or supply of vaccines in the Charlottesville community. Decisions about the rollout of vaccines in the larger community remained with the Virginia Department of Health, working with federal health resources. UVA plays a supporting role in those larger efforts as requested by the VDH. There was no prohibition on students in the delayed vaccination group receiving a COVID-19 vaccine from another source if they become eligible through state guidelines in the interim.